High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer

Gynecologic Oncology

Volumn 98, Issue 1, 2005, Pages 92-98

  Bellone, Stefania ^a   Watts, Katherine ^a   Cane', Stefania ^a   Palmieri, Michela ^b   Cannon, Martin J ^a   Burnett, Alexander ^a   Roman, Juan J ^a   Pecorelli, Sergio ^b   Santin, Alessandro D ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Endometrial cancer; Interleukin 6; Uterine serous papillary carcinoma

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE FUNCTION TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

ADULT; CYSTADENOCARCINOMA, PAPILLARY; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION;

EID: 20444467988     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.03.016     Document Type: Article

References (38)

1. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, and E. Ward Cancer statistics 2004 CA Cancer J. Clin. 54 2004 8 29
2. J.V. Bohkman Two pathogenetic types of endometrial carcinoma Gynecol. Oncol. 15 1983 10 17
3. A.D. Santin, S. Bellone, J.T. O'Brien, S. Pecorelli, M.J. Cannon, and J.J. Roman Current treatment for endometrial cancer Exp. Opin. Anticancer Ther. 4 2004 679 689
4. J.L. Nicklin, and L.J. Copeland Endometrial papillary serous carcinoma: patterns of spread and treatment Clin. Obstet. Gynecol. 39 1996 686 695
5. B.A. Goff, D. Kato, R.A. Schmidt, M. Ek, J.A. Ferry, and H.G. Muntz Uterine papillary serous carcinoma: patterns of metastatic spread Gynecol. Oncol. 54 1994 264 268
6. B.M. Slomovitz, T.W. Burke, P.J. Eifel, L.M. Ramondetta, E.G. Silva, and A. Jhingran Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases Gynecol. Oncol. 91 2003 463 469
7. M.E. Sherman, P. Bitterman, N.B. Rosenshein, G. Delgado, and R.J. Kurman Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathological features Am. J. Surg. Pathol. 16 1992 600 610
8. M.L. Carcangiu, and J.T. Chambers Uterine papillary serous carcinoma: a study on 108 cases with emphasis on prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian cancer Gynecol. Oncol. 47 1992 298 305
9. C. Levenback, T.W. Burke, E. Silva, M. Morris, D.M. Gershenson, and J.J. Kavanagh Uterine papillary serous carcinoma (USPC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC) Gynecol. Oncol. 46 1992 317 321
10. J.K. Chan, V. Loizzi, M. Youssef, K. Osann, J. Rutgers, and S.A. Vasilev Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium Gynecol. Oncol. 90 2003 181 185
11. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am. J. Surg. Pathol. 6 1982 93 108
12. A.D. Santin, F. Zhan, S. Bellone, M. Palmieri, S. Cane', and M. Gokden Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumors by gene expression profiling Br. J. Cancer 90 2004 1814 1824
13. T. Hirano Interleukin 6 and its receptor: ten years later Int. Rev. Immunol. 16 1998 249 284
14. J.Y. Blay, S. Negrier, V. Combaret, S. Attali, E. Goillot, and Y. Merrouche Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma Cancer Res. 52 1992 3317 3322
15. J. Nakashima, M. Tachibana, Y. Horiguchi, M. Oya, T. Ohigashi, and H. Asakura Serum interleukin 6 as a prognostic factor in patients with prostate cancer Clin. Cancer Res. 6 2000 2702 2706
16. G. Scambia, U. Testa, P. Benedetti Panici, E. Foti, R. Martucci, and A. Gadducci Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer Brit. J. Cancer 71 1995 354 356
17. T. Bachelot, I. Ray-Coquard, C. Menetrier-Caux, M. Rastkha, A. Duc, and J.Y. Blay Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients Brit. J. Cancer 88 2003 1721 1726
18. Y. Yamagiwa, C. Marienfeld, F. Meng, M. Holcik, and T. Patel Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival Cancer Res. 64 2004 1293 1298
19. D. Conze, L. Weiss, P.S. Regen, A. Bhushan, D. Weaver, and P. Johnson Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells Cancer Res. 61 2001 8851 8858
20. A. Bongso, B. Gajra, N.P. Lian, P.C. Wong, N. Soon-Chye, and S. Ratnam Establishment of human endometrial cell cultures Hum. Reprod. 3 1988 705 713
21. A.D. Santin, S. Bellone, A. Ravaggi, J.J. Roman, S. Pecorelli, and G.P. Parham Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer Br. J. Cancer 86 2002 151 157
22. M.M. Chan, D. Fong, K.J. Soprano, W.F. Holmes, and H. Heverling Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents J. Cell. Physiol. 194 2003 63 70
23. J. Park, L. Tadlock, G.J. Gores, and T. Patel Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line Hepatology 30 1999 1128 1133
24. Y. Qiu, L. Ravi, and H.J. Kung Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells Nature 393 6680 1998 83 85
25. A.D. Santin HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol. Oncol. 88 2003 263 265
26. A.D. Santin, E.R. Siegel, S. Cane', S. Bellone, M. Palmieri, and M. Thomas Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer Am. J. Obstet. Gynecol. 192 2005 813 818
27. R.E. Bristow, F. Asrari, E.L. Trimble, and F.J. Montz Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease Gynecol. Oncol. 81 2001 279 286
28. K.A. O'Hanlan, P.A. Levine, D. Harbatkin, C. Feiner, G.L. Goldberg, and J.G. Jones Virulence of papillary endometrial carcinoma Gynecol. Oncol. 37 1990 112 119
29. J.P. Geisler, H.E. Geisler, M.E. Melton, and M.C. Wiemann What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol. Oncol. 74 1999 465 467
30. G. Schuler, and R.M. Steinman Dendritic cells as adjuvants for immune-mediated resistance to tumors J. Exp. Med. 186 1997 1183 1187
31. F.O. Nestle, S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, and R. Dummer Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat. Med. 4 1998 328 332
32. B. Thurner, I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, and H. Jonuleit Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J. Exp. Med. 190 1999 1669 1678
33. A. Kugler, G. Stuhler, P. Walden, G. Zoller, A. Zobywalski, and P. Brossart Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids Nat. Med. 6 2000 332 336
34. E.J. Small, P. Fratesi, D.M. Reese, G. Strang, R. Laus, and M.V. Peshwa Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J. Clin. Oncol. 18 2000 3894 3903
35. J.D. Geiger, R.J. Hutchinson, L.F. Hohenkirk, E.A. McKenna, G.A. Yanik, and J.E. Levine Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression Cancer Res. 61 2001 8513 8519
36. M.V. Dhodapkar, R.M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells J. Exp. Med. 193 2001 233 238
37. C. Menetrier-Caux, G. Montmain, M.C. Dieu, C. Bain, M.C. Favrot, and C. Caux Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor Blood 92 1998 4778 4791
38. P. Chomarat, J. Banchereau, J. Davoust, and A.K. Palucka IL-6 switches the differentiation of monocytes from dendritic cells to macrophages Nat. Immunol. 1 2000 510 514